How Investors Are Reacting To Krystal Biotech (KRYS) Surging Revenue and Global VYJUVEK Expansion

• Krystal Biotech recently reported strong third quarter 2025 results, attributing improved gross margins and significant revenue growth to its lead product VYJUVEK and streamlined manufacturing operations.
• Management also emphasized accelerating global expansion, launching VYJUVEK in markets such as Germany, France, and Japan, and forming distribution partnerships across multiple regions to improve patient access for dystrophic epidermolysis bullosa treatment.
• We will now explore how Krystal’s operational efficiency and international rollout of VYJUVEK could reshape its broader investment case.

We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Krystal Biotech Investment Narrative Recap

To be a shareholder in Krystal Biotech, you need to believe that international market expansion and improved operational efficiency will fuel sustained revenue and profit growth, largely tied to the ongoing momentum of VYJUVEK. The recent quarter’s strong results reinforce VYJUVEK’s status as the most important catalyst, but they do not resolve the major risk, persistent quarter-to-quarter volatility due to unpredictable patient treatment dynamics and heavy product concentration.

Among recent announcements, the marketing authorization of VYJUVEK in Japan stands out. This regulatory win is closely linked to the current news, as it expands Krystal’s market reach at a critical time and could drive near-term revenue while sharpening the focus on access and reimbursement as key variables in the overall growth outlook.

However, even with global rollout gaining steam, investors should not lose sight of...

Read the full narrative on Krystal Biotech (it's free!)

Krystal Biotech's outlook anticipates $849.4 million in revenue and $485.8 million in earnings by 2028. This implies a 33.2% annual revenue growth rate and an earnings increase of $339.1 million from current earnings of $146.7 million.

Uncover how Krystal Biotech's forecasts yield a $223.00 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Four community contributors on Simply Wall St provided fair value estimates for Krystal Biotech ranging from US$176 to US$476, reflecting sharply differing views on the company’s potential. With the business still highly reliant on VYJUVEK’s launch and uptake, expect sentiment, and the path forward for earnings, to be closely linked to headline catalysts and risks in its international expansion.

Explore 4 other fair value estimates on Krystal Biotech - why the stock might be worth over 2x more than the current price!

Build Your Own Krystal Biotech Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Krystal Biotech research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Krystal Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Krystal Biotech's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com